Edgewise Shares Fall Despite Encouraging Phase 2 Results in Obstructive and Nonobstructive HCM

Edgewise shared encouraging Phase 2 CIRRUS-HCM results for EDG-7500, showing strong improvements in symptoms, biomarkers, and diastolic function across both types of HCM. Larger Phase 3 trials will be required before any approval.